Finance

Lists
SBMFF:OTCMKTS
Sino Biopharmaceutical Ltd
$0.70
-0.14%
(-0.00095) 1D
Sep 11, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SBMFF...
Open
$0.70
High
$0.70
Low
$0.70
Mkt. cap
98.09B
Avg. vol.
1.25K
Volume
1.00K
52-wk high
$1.16
52-wk low
$0.60
Beta
0.58
Shares outstanding
18.68B
No. of employees
23K
Open
$0.70
High
$0.70
Low
$0.70
Mkt. cap
98.09B
Avg. vol.
1.25K
Volume
1.00K
52-wk high
$1.16
52-wk low
$0.60
Beta
0.58
Shares outstanding
18.68B
No. of employees
23K
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees22.8K
Founded2000
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.13B
7.13B
9.72B
9.72B
Cost of goods sold
1.31B
1.31B
1.65B
1.65B
Cost of revenue
1.31B
1.31B
1.65B
1.65B
Research and development expenses
2.93B
2.93B
1.54B
1.54B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.80B
2.80B
3.11B
3.11B
Operating expense
4.38B
4.38B
4.77B
4.77B
Total operating expenses
5.69B
5.69B
6.42B
6.42B
Operating income
1.44B
1.44B
3.31B
3.31B
Other non operating income
97.99M
97.99M
76.64M
76.64M
EBT including unusual items
488.22M
488.22M
3.67B
3.67B
EBT excluding unusual items
1.55B
1.55B
3.56B
3.56B
Income tax expense
323.77M
323.77M
597.96M
597.96M
Effective tax rate
66.32%
66.32%
16.29%
16.29%
Other operating expenses
-1.35B
-1.35B
113.21M
113.21M
Net income
-522.62M
-522.62M
1.72B
1.72B
Net profit margin
-7.33%
-7.33%
17.66%
17.66%
Earnings per share
-
-
-
-
Interest and investment income
196.36M
196.36M
250.06M
250.06M
Interest expense
-77.56M
-77.56M
-84.75M
-84.75M
Net interest expenses
118.80M
118.80M
165.31M
165.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.66B
1.66B
3.55B
3.55B
Gain or loss from assets sale
-5.58M
-5.58M
-
-
AI content may include mistakes. Learn more
Google apps